Literature DB >> 35352410

Pituitary MRI in Cushing's disease - an update.

Jean-François Bonneville1, Iulia Potorac2, Patrick Petrossians2, Luaba Tshibanda1, Albert Beckers2.   

Abstract

Pituitary MRI is essential in the diagnosis of ACTH-dependent Cushing's syndrome, but its results are inconsistent. The demonstration of a sellar image compatible with the diagnosis of corticotropinoma varies from 40% to 90%, depending on the centre where the imaging is performed. In fact, the expertise of the neuroradiologist, use of a Tesla 3.0 MRI and choice of sequences are fundamental. The T2 and 3D gradient echo sequences after gadolinium injection are the most informative and today allow the detection of macro- and microadenomas in almost all cases. The diagnosis of numerous picoadenomas (<3-4 mm) is more challenging. The 2D and 3D spin echo or delayed T1 SE or FLAIR sequences after gadolinium can be used as a complement or to confirm a suspicious image. Characterization of corticotropinomas remains problematic. However, the correct assessment of so-called incidentalomas by recognizing artifacts, anatomical variants and frequent Rathke's cleft cysts eliminates around 90% of the incidentalomas that mimic pituitary adenomas, as repetitively reported in the literature. For the time being, there is reason to believe that hybrid imaging combining PET and MRI such as 11C-methionine PET coregistered with volumetric MRI will solve the diagnosis of corticotropinomas in the near future.
© 2022 British Society for Neuroendocrinology.

Entities:  

Keywords:  Cushing's disease; pituitary MRI

Mesh:

Substances:

Year:  2022        PMID: 35352410     DOI: 10.1111/jne.13123

Source DB:  PubMed          Journal:  J Neuroendocrinol        ISSN: 0953-8194            Impact factor:   3.870


  7 in total

Review 1.  Modern imaging in Cushing's disease.

Authors:  W A Bashari; D Gillett; J MacFarlane; A S Powlson; A G Kolias; R Mannion; D J Scoffings; I A Mendichovszky; J Jones; H K Cheow; O Koulouri; M Gurnell
Journal:  Pituitary       Date:  2022-06-06       Impact factor: 3.599

2.  Cushing's Disease Management: Glimpse Into 2051.

Authors:  Rinkoo Dalan; Stefan R Bornstein; Bernhard O Boehm
Journal:  Front Endocrinol (Lausanne)       Date:  2022-07-06       Impact factor: 6.055

Review 3.  Distinguishing Cushing's disease from the ectopic ACTH syndrome: Needles in a haystack or hiding in plain sight?

Authors:  Aimee R Hayes; Ashley B Grossman
Journal:  J Neuroendocrinol       Date:  2022-08-18       Impact factor: 3.870

Review 4.  Aggressive corticotroph tumors and carcinomas.

Authors:  Hélène Lasolle; Alexandre Vasiljevic; Emmanuel Jouanneau; Mirela Diana Ilie; Gérald Raverot
Journal:  J Neuroendocrinol       Date:  2022-08-18       Impact factor: 3.870

Review 5.  Long-term effects of glucocorticoid excess on the brain.

Authors:  Alies J Dekkers; Jorge Miguel Amaya; Merel van der Meulen; Nienke R Biermasz; Onno C Meijer; Alberto M Pereira
Journal:  J Neuroendocrinol       Date:  2022-08-18       Impact factor: 3.870

Review 6.  The diagnosis and management of Cushing's syndrome in pregnancy.

Authors:  Ross Hamblin; Amy Coulden; Athanasios Fountas; Niki Karavitaki
Journal:  J Neuroendocrinol       Date:  2022-05-01       Impact factor: 3.870

Review 7.  Cardiovascular complications of Cushings syndrome: Impact on morbidity and mortality.

Authors:  Richard N Clayton
Journal:  J Neuroendocrinol       Date:  2022-06-28       Impact factor: 3.870

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.